di-tert-butyl N-(4-formylbenzoyl)-L-glutamate | 87597-84-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: di-tert-butyl N-(4-formylbenzoyl)-L-glutamate
• 英文别名: di-tert-butyl (4-formylbenzoyl)-L-glutamate；di-t-butyl N-(4-formylbenzoyl)-L-glutamate；ditert-butyl (2S)-2-[(4-formylbenzoyl)amino]pentanedioate
• CAS: 87597-84-0
• 化学式: C₂₁H₂₉NO₆
• 分子量: 391.464
• InChiKey: CHZSDVMWLWKNGU-INIZCTEOSA-N

物化性质

• 沸点：
  539.3±50.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  98.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  di-tert-butyl N-(4-formylbenzoyl)-L-glutamate 在 镍 盐酸 、 氢气 、 sodium cyanoborohydride 、 溶剂黄146 、 三氟乙酸 作用下， 反应 1.0h， 生成 5,8-dideazaisoamethopterin
  参考文献：
  名称：

  叶酸的经典2,4-二氨基喹唑啉类似物的化学和抗肿瘤评估。

  摘要：

  通过明确的途径合成了一系列六种叶酸的2，4-二氨基喹唑啉类似物，它们与甲氨蝶呤1a的结构相似。其中的三个以前没有进行过描述，而首次显示了其余化合物的完整结构特征。每种化合物都是来自大鼠肝脏或L1210白血病细胞的二氢叶酸还原酶（DHFR）的有效抑制剂，其I50值与1a相似。然而，在体外观察到的对人胃肠道腺癌或L1210白血病细胞生长的抑制活性差异很大。在位置9和10具有正常叶酸构型的化合物比其异构体反向桥对应物更具抑制作用。N-甲酰基修饰是所研究化合物中活性最低的。未取代或N-甲基修饰可与effectively化1a竞争进入L1210白血病细胞的有效竞争，而N-甲酰基修饰则不能。对于由于改变的转运和DHFR的过量产生而对1a具有抗性的L1210细胞系，对于某些类似物观察到部分但不完全的交叉抗性。在用于体内评估小鼠L1210白血病的三种化合物中，两种具有与1a相似的抗肿瘤活性。然而，化合物5

  DOI：

  10.1021/jm00380a011
• 作为产物：
  描述：

  L-谷氨酸二叔丁酯盐酸盐 、 对醛基苯甲酸 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.25h， 以88%的产率得到di-tert-butyl N-(4-formylbenzoyl)-L-glutamate
  参考文献：
  名称：

  设计和合成包含桥接酯基的二氢叶酸还原酶抑制剂。在小鼠结肠炎模型中的评估。

  摘要：

  克罗恩氏病是一种慢性炎症性肠病，其特征是小肠和大肠都发炎。甲氨蝶呤（MTX）是一种经典的二氢叶酸还原酶（DHFR）抑制剂，近年来已被用作克罗恩病患者的治疗剂。我们试图开发结构类似于MTX的抗叶酸药，该药可有效减轻结肠炎的小鼠疾病模型中的炎症。合成了在分子中心部分包​​含酯桥的四种经典DHFR抑制剂。这些抗叶酸剂是源自大鼠的DHFR酶的有效抑制剂。还体外测试了它们抑制小鼠脾淋巴细胞诱导的增殖的能力。仅在微摩尔范围内才能达到抑制细胞增殖的作用，而MTX在低纳摩尔浓度下有效。选择一种DHFR抑制剂（1），其rlDHFR的IC（50）值比甲氨蝶呤高约8倍，用于小鼠实验性结肠炎模型的体内实验。该化合物在局部给药后表现出明显的抗炎作用，与糖皮质激素布地奈德所达到的作用相当。在该模型中评估了三个参数：髓过氧化物酶活性，结肠重量和炎症评分。在所有三个炎症参数中均观察到化合物1的体内有益作用（15 mg /（kg

  DOI：

  10.1021/jm021062y

文献信息

• Synthesis of 5-trifluoromethyl-5,8-dideazafolic acid and 5-trifluoromethyl-5,8-dideazaisofolic acid
  作者：Shyam K. Singh、Meledath Govindan、John B. Hynes

  DOI：10.1002/jhet.5570270746

  日期：1990.11

  The target folate analogue 5-trifluoromethyl-5,8-dideazafolic acid has been elaborated in a seven-step reaction sequence beginning with 2-fluoro-6-trifluoromethylbenzonitrile. The bridge-reversed isomer 5-trifluoromethyl-5,8-dideazaisofolic acid was prepared in six steps using the common intermediate 2,6-diamino-3,4-dihydro-4-oxo-5-trifluoromethylquinazoline. The key intermediate 2-amino-3,4-dihyd

  以2-氟-6-三氟甲基苄腈为起始原料，以七步反应的顺序对目标叶酸类似物5-三氟甲基-5,8-二氮杂萘甲酸进行了详细的阐述。使用普通中间体2,6-二氨基-3,4-二氢-4-氧代-5-三氟甲基喹唑啉，分六个步骤制备了桥反异构体5-三氟甲基-5,8-二叠氮基异叶酸。使用两种不同的合成途径制备了关键中间体2-氨基-3,4-二氢-4-氧代-5-三氟甲基-喹唑啉，发现得到的产物是相同的。
• Improved synthesis and antitumor evaluation of 5,8-dideazaisofolic acid and closely related analogs
  作者：J. B. Hynes、Y. C. S. Yang、J. E. McGill、S. J. Harmon、W. L. Washtien

  DOI：10.1021/jm00368a023

  日期：1984.2

  A new synthetic route to 5,8-dideazaisofolic acid (IAHQ) is described which precludes the possibility of contamination due to its 4-amino counterpart 5,8-dideazaisoaminopterin. Substitution of D-glutamic acid in this synthetic scheme gave D-IAHQ. The 9-formyl, 9-methyl, 5-methyl, and 5,9-dimethyl modifications of IAHQ were also prepared. These compounds, together with several structurally related or

  描述了一种新的合成途径，即5,8-二叠氮基异叶酸（IAHQ），由于其4-氨基对应物5,8-二叠氮基异氨基蝶呤而避免了污染的可能性。在该合成方案中用D-谷氨酸取代得到D-IAHQ。还制备了IAHQ的9-甲酰基，9-甲基，5-甲基和5,9-二甲基修饰。研究了这些化合物以及几种结构上相关或异构的类似物对四种人胃肠道腺癌细胞系体外生长的抑制作用。通常，在9和10位具有正常叶酸构型的化合物比其反向桥异构体具有更高的活性。D-IAHQ抗肿瘤活性的缺乏提供了有关IAHQ作用机理的间接证据。
• Synthesis and preliminary biological evaluation of 5-fluoro-5,8-dideazaisoaminopterin
  作者：Alenka Tomažič、John B. Hynes、Glen R. Gale、James H. Freisheim

  DOI：10.1002/jhet.5570270742

  日期：1990.11

  The new folate antagonist, 5-fluoro-5,8-dideazaisoaminopterin was synthesized in four steps beginning with 2,4-diamino-5-fluoroquinazoline. It was found to be a potent inhibitor of human dihydrofolate reductase. Against L1210 leukemia in mice, 5-fluoro-5,8-dideazaisoaminopterin was equiactive with methotrexate at approximately one half of the total dose employed.

  从2,4-二氨基-5-氟喹唑啉开始，分四个步骤合成了新的叶酸拮抗剂5-氟-5,8-二氮杂异氨基蝶呤。发现它是人二氢叶酸还原酶的有效抑制剂。针对小鼠中的L1210白血病，5-氟-5,8-二氮杂异氨基蝶呤与甲氨蝶呤的活性相等，约为所用总剂量的一半。
• Studies on the antitumor effects of analogues of 5,8-dideazaisofolic acid and 5,8-dideazaisoaminopterin
  作者：Robert L. Hagan、John B. Hynes、Meade Pimsler、Roy L. Kisliuk

  DOI：10.1016/0006-2952(95)00203-c

  日期：1995.9

  Six new analogues of 5,8-dideazaisofolic acid and 5,8-dideazaisoaminopterin were synthesized in an effort to obtain enhanced antitumor activity. The modifications included the replacement of the 2-amino group by hydrogen or methyl as well as the inclusion of a methyl substituent at position 9. Based upon activity against L1210 leukemia cells in culture, three of the new analogues together with one compound described previously were evaluated for cytotoxicity in vitro using three human tumor cell lines (Cole 320 DM, Hep G2 and HL-60). The most effective compound was 2-desamino-N-9-methyl-5,8-dideazaisoaminopterin (2c) with the HL-60 cells being the most sensitive to its cytotoxic effects. These analogues were evaluated in vitro as inhibitors of dihydrofolate reductase (DHFR) and thymidylate synthase (TS) from human as well as bacterial (Lactobacillus casei) sources. All four of the 4-amino analogues were most effective toward L. casei DHFR compared with human DHFR, with 2-desamino-2-methyl-5,8-dideazaisoaminopterin (2d) and its 9-methyl derivative (2e) having 818- and 430-fold greater selectivity (L. caseilhuman). Most of the compounds studied were found to be only modest inhibitors of human TS (I-50 values = 1.5 to 20 mu M) and were therefore at least 40-fold less inhibitory than 10-propargyl-5,8-dideazafolic acid. Nevertheless, reversal of cytotoxicity studies with thymidine, hypoxanthine and folinic acid using the HL-60 cell line suggested that TS is the primary target for these analogues.
• Synthesis and biological evaluation of 5-deazaisofolic acid, 5-deaza-5,6,7,8-tetrahydroisofolic acid, and their N9-substituted analogues
  作者：Shyam K. Singh、Inderjit K. Dev、David S. Duch、Robert Ferone、Gary K. Smith、James H. Freisheim、John B. Hynes

  DOI：10.1021/jm00106a021

  日期：1991.2

  Prompted by recent disclosures concerning the potent antitumor activities of 5-deaza-5,6,7,8-tetrahydrofolic acid and 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF), we have prepared 5-deazaisofolic acid (3a) and 5-deaza-5,6,7,8-tetrahydroisofolic acid (4a). Reductive condensation of 2,6-diamino-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidine with di-tert-butyl N-(4-formylbenzoyl)-L-glutamate and subsequent deprotection with trifluoroacetic acid yielded 5-deazaisofolic acid in good yield. Catalytic hydrogenation of this analogue then gave 4a. The 9-CH3 and 9-CHO modifications of 3a and the 9-CH3 derivative of 4a were also synthesized. Each of the new analogues was evaluated with a variety of folate-requiring enzymes as well as MCF-7 cells in culture. Compound 4a had an IC50 of ca. 1-mu-M against MCF-7 cells and was nearly 100-fold less potent than DDATHF in this regard. The three oxidized isofolate analogues were all poor inhibitors of tumor cell growth.